Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type" D6 O' l" h, U6 I% l) Q3 v/ N9 H
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
2 _3 @3 Q d2 Y6 `. p7 @6 @+ Author Affiliations) k# z2 x8 s7 x
6 L* M4 D e a* q1 M3 b6 t, `1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
! S1 \4 ^% Y$ W1 ~' q9 Y ?2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 9 E% D* {6 C A! y+ T# P* z( X
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
" S: t4 Z. ]7 O1 ?1 N% s' U9 T1 d0 z4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan " |% D. G$ a( i$ L& P5 ]' |
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
% k! ?6 N0 e: i( y. G6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
) v! A$ i. K0 t7Kinki University School of Medicine, Osaka 589-8511, Japan 4 u9 b; E1 Z0 J, E: ?8 G q
8Izumi Municipal Hospital, Osaka 594-0071, Japan
K {8 p) ~. W5 }* k6 T5 ]4 R9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
# q5 c& i+ O* [( Y& M$ MCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp _$ Y9 l9 z1 d6 v
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 9 U( ?4 [. t. O. K/ ?
) G! p/ p; b; \# F/ n" `1 G+ T
|